HadaClinic Web Journal: Thalidomide & CelecoxibFlung adenocarcinoma
Chemotherapeutic Strategy with the Interaction of Gut-Organs Axis and Tumor microenvironment for Lung Adenocarcinoma
Association between microbiota, chronic inflammation, angiogenesis and cancer
Masato Hada, MD, Pharmacist
Hada Clinic, email@example.com
40% of lung cancer is adenocarcinoma and is aggressive and fatal 1. At present, correlations between salivary microbiota and lung cancer could be predicted to be proved 2. Probiotics, orally administered, may reduce periodontal pathogens in the subgingival microbiota 3.
Lung adenocarcinoma is regulated by a variety of oncogenic factors that are effective therapeutic targets for targeted therapies 4. Immune system is significantly relevant to gut and salivary microbiota, which is also associated with gut and salivary lung axis in tumor microenvironment (TME). NF-ÈB plays pivotal role in gut-organs axis and tumor cells in TME. It might be possible to prevent carcinogenesis, proliferation, and metastasis by modulating irregulated or activated NF-ÈB.
Key words :@ gut-organs axis, thalidomide, celecoxib, valproic acid, probiotics, NF-ÈB
Microbiota comprising bacteria, virus, and fungi plays an important role in health and carcinogenesis 5 6. More than 600 bacterial species are known to reside in oral cavity. These microorganisms play an important role in maintaining not only oral health but also systemic health including lung, digestive tract and cardiovascular system. Therefore, dysbiosis in oral microbiota triggers local and systematic diseases 7. Microbiota gut-lung axis is the bi-directional cross-talk between gut and lung and dysbiosis drives allergy, asthma and cystic fibrosis 8.
Multiple angiogenic signaling pathways and their interactive loops drive@chronic@inflammation that induce carcinogenesis, proliferation, and metastasis through@angiogensis in more than 20-30 years.11
Lung adenocarcinoma is regulated by oncogenic factors including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK that are effective therapeutic targets for chemotherapies12.
Oral bacteria are important to maintain oral health. However, dysbiosis induces periodontitis especially in cigarette smokers. Oral dysbiosis also increases systemic diseases including lung, digestive tract and cardiovascular system 13 14 15.
Gut, brain, and lung are intimately linked organs and they maintain homeostasis through cross-talks, e.g. microbiota gut-brain axis and gut-lung axis. The metabolites produced by gut microbiota cross-talk with lung through lymph or blood stream (gut-lung axis) 8. Two Firmicutes and Bacteroidetes reside predominantly in the respiratory airways, however, the lower respiratory tract is one of the least habitat 16. Fusobacterium nucleatum, Escherichia coli, Bacteroides fragilis, and Proteobacteria are demonatrated to relevant to carcinogenesis, and Fusobacterium may contribute to the development of lung cancer 17 18. Smoking promotes chronic inflammation which triggers increased macrophage recruitment, delayed neutrophil clearance, and increase in reactive oxygen species (ROS). This pulmonary microenvironment is seemed to be induced by pulmonary and gut microbiota 15 19. Chronic inflammation induced by infections and non-infectious agents including smoking promotes the release of cytokines and growth factors by alveolar macrophages, lymphocytes, neutrophils, endothelial cells, and fibroblasts 20. These factors including P-53, NF-kB, VEGF, FGF, and COX-2 drive epithelial dysfunction, carcinogenesis and malignant progression 19.
p53 is a major tumor suppressor, mutant p-53 in tumors promotes tumor progression and resistance to anticancer agents when losing the tumor suppressor functions of wild-type p53, this function is referred to mutant p53 gain-of-function 21. COX-2 regulates P-53, and inhibition of COX-2 may be a proper option for treatment, however inhibition of COX-2 with celecoxib may increase chemoresistance in lung cancer cells 22.
The nuclear factor (NF)-ÈB family is ubiquitous transcription factor and functions to regulate the expression of more than 150 genes defensing cellular processes including inflammation, immunity, cell proliferation, differentiation, and survival 23 24. The irregulated or activated of NF-ÈB are associated with various pathological conditions especially included in infections and malignancies. Two major signaling pathways, canonical and noncanonical (or alternative) pathways are crucial for activation of NF-ÈB 25.
Pathogens including bacteria and parasites activate the NF-ÈB signalling pathway for tumor cell proliferation, survival, migration, inflammation, and angiogenesis 26.
Immune homeostasis in epithelial tissues such as the skin and the intestine are maintained by NF-ÈB signaling pathways. Deregulated NF-ÈB triggers severe TNF-dependent skin inflammation and epidermal hyperplasia in keratinocytes and also triggers severe chronic colon inflammation disturbing the intestinal barrier in intestinal epithelial tissues 27.
Various carcinogens including cigarette smoking cause DNA damage in lung epithelial cells and simultaneously during damaged DNA repair, chronic inflammation in lung tissue is induced by activated NF-ÈB through the canonical pathway. Deregulated NF-ÈB causes cancer by producing cytokines including a variety of interleukins and TNF-¿ 28. Hypoxia-inducible factor (HIF) family upregulates the angiogenic growth factors that stimulate angiogenesis in response to hypoxia 29. Angiogenesis drives tumor growth, metastasis and is related to poor prognosis. VEGF, bFGF and COX-2 are three key mediators of angiogenesis 30 31. Therapeutic development of antiangiogenic agents for the treatment of cancer should be aimed to block multiple angiogenic signaling pathways and their interactive loops 32 33.
Treatment with antiangiogenic agents, especially targeting VEGF have advanced recently. Targeting angiogenesis, however, has not proven to be as efficacious as originally hoped 32. The significant effect could not be expected because the drugs are not selected according to the following mechanism of action. Antiangiogenic pathways are significantly complicated with a variety of factors. Moreover, the agents now used target the receptors and factors of upstream pathways till transcriptional factors, not pivotal transcriptional factor NF-ÈB.
The NF-ÈB signalling pathways are attractive targets for the treatment of malignancies by anti-NF-ÈB agents such as thalidomide and celecoxib.
Tumor microenvironment (TME) is the functional malignant tissue in which malignant and non-malignant cells communicates via a complex and dynamic network. This network is driven via cytokines, chemokines, growth factors, and inflammatory and matrix remodeling enzymes 34.
Tumor associated fibroblasts play a critical role in the network. The fibroblasts secrete growth factors and chemokines such as altered extracellular matrix (ECM) enhancing cancer-cell proliferation and invasion. The other cells composing of TME are immune and inflammatory cells, blood and lymph vessels, and nerves 35. The VEGF family consists of five members (VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and platelet derived growth factor (PDGF) and they bind with three receptor tyrosine kinases (VEGFR-1, -2 and -3). After the link inducing endothelial cell migration, proliferation, vascular permeability, and tube formation are induced after the link between VEGFA and VEGFR. Bevacizumab, humanized monoclonal antibody to VEGF-A, has been described in a number of studies that this agent has provided significant benefit to cancer patients 36. But this agent only inhibits VEGFR-1 andVEGF-2 and also cannot control the complex network of signaling cascades and cannot transmit signals to NF-ÈB that drive angiogenesis and lymphangiogenesis.
FGFs are pleiotropic molecules that can act on a variety of cell types. Different from VEGF, FGFs induce angiogenesis and arteriogenesis with other growth factors such as VEGF, PDGF, and FGF in cardiomyocyte, stromal cells and endothelial cells 37. COX-2 expression is induced in a variety of cells including the neoplastic cells, endothelial cells, immune cells, and stromal fibroblasts within malignant tumors. COX-2 triggers the production of thromboxane A2 (TXA2), prostaglandin E2 (PGE2), and prostaglandin I2 (PGI2) through arachidonic metabolism. These eicosanoid products promote angiogensis with other growth factors such as VEGF, Bcl-2, and matrix metalloproteinases 38.
Cisplatin based doublet chemotherapy is effective as first-line chemotherapy providing a survival benefit and symptom relief in patients with inoperable non-small-cell lung cancer (NSCLC). Currently anticancer agents including irinotecan, paclitaxel, docetaxel, gemcitabine, and vinorelbine are considered standard chemotherapy regimens for advanced NSCLC 39.
Signalling pathways VEGF, PDGF and FGF pathways could be the targets of valid anti-cancer drug targets. However many agents, including monoclonal antibodies (ending –mab like nivolumabCbevacizumab), and inhibitory agents(ending –ib like solafenib) have failed to show clinically meaningful benefits 40. The carcinogenic signals pass through complicated and loop pathways. Carcinogenesis may be attained in more than 10-30 years with weak signals.
Monoclonal antibody: Nivolumab
Monoclonal antibody nivolumab is an immune checkpoint inhibitor blocks PD-1 and promotes antitumor response and is thought to be clinically meaningful agent with median overall survival (mOS) 9.6 months for SCLC. However, the intracellular signal pathways after docking nivolumab with extracellular receptors till transcriptional factors are not elucidated.
The CheckMate 057 trial demonstrated improved OS compared with docetaxel: a median OS of 12.2 months in patients treated with nivolumab compared with 9.4 months with docetaxel 41. This OS is statistically significant improvement but not clinically meaningful benefits for the patients. Microbiota improves anti-tumor immune response and promotes the efficacy of immune checkpoint inhibitors 42. This may be supposed to be caused by the suppression of activated NF-kB in macrophage 43.
Sorafenib is a multitargeted signal transduction inhibitor that inhibits Raf-Kinase, VEGF receptor-2, PDGF receptor-B, and c-kit. Clinical benefits of the combination of sorafenib and cytotoxic agents have been studied, however no benefit was demonstrated from adding sorafenib to cytotoxic regimens for NSCLC 44.
Toll-like receptors and NF-kB
Toll-like receptors and NF-kB play a crucial role in the progress of inflammation and cancer such as carcinogenesis, proliferation, and metastasis. Molecular targeted anticancer agents targeting these two factors make the regimen more effective with cytotoxic agents.
Cytotoxic chemotherapy, either as a platinum-based doublet or as a single agent, remains the standard therapeutic approach with metastatic NSCLC. There are no statistically significant differences and benefits among these regimens 45.
Other approaches with new agents that have different mechanism from standard chemotherapy must be warranted.
Transcription factor HIF family activates proangiogenic factors such as VEGF, FGF, COX-2, and interleukin-8 46. These factors are produced through activated or irrgulated NF-kB. It is important to use the agents that act on transcriptional factors or their downstream factors 47.
JAK/STAT MAPK/ERK pathway
limited intestinal absorption
* The most active agents are: Texans, Gemcitabine, Vinorelbine, Irinotecan
The exciting findings in the past decade are that the gut microbiota may act as a regulator of the malignant cell resistance to cytotoxic agents. At least it is important to maintain the homeostasis of gut microbiota with probiotics, prebiotics and berberine 56. The key factor that acts and promotes the secretions of cytokines in macrophage and angiogenic factors in tumor cells is NF-ÈB. This factor is the pivotal chemotherapeutic target.
The fermentation that exert beneficial effects in human health are known as probiotics which are defined as live microbial feed supplements including the genus Lactobacillus and Bifidobacterium. Probiotics have been shown to have anticancer effects with prebiotics 57.
The microbial fermentation of dietary fiber@may lead to the increased production of short-chain fatty acids (SCFAs) including acetate, propionate, and butyrate. The potential natural products containing dietary fiber are whole grains, fruits, vegetables, and nuts. SCFAs contribute to energy consumption and mucosal protection against pathogens through enteroendocrine L cells that secrete GLP-1 and PYY 58. SCFAs are known as histone deacetylas (HDAC) inhibitors, especially butyrate possesses significant response and modulates cancer and immunological stability57.
Berberine is an isoquinoline alkaloid purified from Japanese herb, Phellodendron amurense (KIHADA in Japanese), for a treatment of microbial diarrhea damaging the structure of bacterial cell membrane 48. The antiinflammatory activity of berberine is induced via AMP-activated protein kinase (AMPK) activation, NF-kB inhibition and AP-1 pathway inhibition 59. The inhibition of these pathways by berberine plays a critical role in inflammation and carcinogenesis resulting in down-regulating the expression of cytokines, including TNF-¿, IL-1À, IL-6, monocyte chemo-attractant protein-1 (MCP-1), inducible nitric oxide synthase (iNOS), and COX-2 60. Berberine is an agent with little side effects, becasue it is hard to be absorbed from gut. Various studies have demonstrated that berberine modulate the gut microbiota through short chain fatty acids(SCFAs) production and SCFSs work as gut-organs axis with various organs through peptides including GLP-1, GLP-2, and PYY after the damage of bacterial cell membrane 61.
Thalidomide is an immunomodulatory agent with strong antiangiogenic properties with COX-2 inhibitor celecoxib 62. Thalidomide inhibits the mRNA encoding such as TNF-¿ and VEGF 63. In addition, thalidomide modulates activated or irregulated NF-ÈB, resulting in suppressing malignant cell proliferation and angiogenesis as well as invasion and metastasis 64.
COX-2 is constitutively overexpressed in chronic inflammation including premalignant, malignant, and metastatic tumors. Chronic inflammation induced by pathogens and metabolic state such as obesity leads to express COX-2. Produced prostaglandin and proinflammatory cytokines by COX-2 cause angiogenesis with subsequent carcinogenesis, tumor proliferation and metastasis, especially through NF-ÈB 65 66.
VPA is a short fatty acid and has been used as an anticonvulsant agent. In recent years, VPA is used as HDAC inhibitor alone or in combination with other anticancer agents 67. The structural change of histone by methylation or acetylation facilitates or inhibits the access of transcriptional factors. HDAC inhibitors have been used for cancer therapy and the combination of epigenetic agents and other anticancer agents may increase the efficacy 68 69.
The induction of cell cycle arrest and apoptosis by VPA are associated with increased expression of E-cadherin and decreased expression of VEGF and MMP-9 70. VPA inhibits endothelial function and angiogenesis 71.
The ultimate goal of Cancer Prevention and Treatment is to mediate pathogens binding to Toll-like receptors and to select the agents that act on transcriptional factors such as NF-ÈB.
1. Thalidomide Celecoxib
Small molecular inhibitors that work between transcriptional factors and various downstream signaling molecules
2. Epigenetic agent
Valproic acid (600mg/day)
3. Cytotoxic agents with low dose
Texans, Gemcitabine, Vinorelbine, Irinotecan
4. Downregulate pro-inflammatory cytokines
Berberine 100-300mg/day p.o
1.Denisenko TV, Budkevich IN, Zhivotovsky B.
Cell death-based treatment of lung adenocarcinoma.
Cell Death Dis. 2018 Jan 25;9(2):117.
2. Junjie Yang,1,2 Xiaofeng Mu,3,4,5 Ye Wang,, et al
Dysbiosis of the Salivary Microbiome Is Associated With Non-smoking Female Lung Cancer and Correlated With Immunocytochemistry Markers
Front Oncol. 2018; 8: 520.
3. Iniesta M, Herrera D, Montero E, et al
Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial.
J Clin Periodontol. 2012 Aug;39(8):736-44.
4. Chan BA, Hughes BG.
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
Transl Lung Cancer Res. 2015 Feb;4(1):36-54.
5. Raza MH, Gul K, Arshad A, et al
Microbiota in cancer development and treatment.
.J Cancer Res Clin Oncol (2019) 145: 49.
6. Beck JM, Young VB, Huffnagle GB.
The microbiome of the lung.
Transl Res. 2012 Oct;160(4):258-66.
7. Gao L, Xu T, Huang G, et al
Oral microbiomes: more and more importance in oral cavity and whole body.
Protein Cell. 2018 May;9(5):488-500.
8. S. Anand, S. S. Mande
Diet, Microbiota and Gut-Lung Connection
Front Microbiol. 2018; 9: 2147.
9. Johannesson M, Askling J, Montgomery SM, et al
Cancer risk among patients with cystic fibrosis and their first-degree relatives.
Int J Cancer. 2009 Dec 15;125(12):2953-6.
10. Neglia JP, FitzSimmons SC, Maisonneuve P, et al
The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group.
N Engl J Med. 1995 Feb 23;332(8):494-9.
11. Sever R, Brugge JS.
Signal transduction in cancer.
Cold Spring Harb Perspect Med. 2015 Apr 1;5(4). pii: a006098.
12. Bansal P, Osman D, Gan GN, et al
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Front Oncol. 2016 May 4;6:112.
13. Ogawa T, Hirose Y, Honda-Ogawa M, et al
Composition of salivary microbiota in elderly subjects.
Sci Rep. 2018 Jan 11;8(1):414.
14. Koch CD, Gladwin MT, Freeman BA, et al
Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.
Free Radic Biol Med. 2017 Apr;105:48-67.
15. Mur LA, Huws SA, Cameron SJ, et al
Lung cancer: a new frontier for microbiome research and clinical translation.
Ecancermedicalscience. 2018 Sep 5;12:866.
16. Marsland BJ, Trompette A, Gollwitzer ES.
The Gut-Lung Axis in Respiratory Disease.
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2:S150-6.
17. Zhang WQ, Zhao SK, Luo JW, et al
Alterations of fecal bacterial communities in patients with lung cancer.
Am J Transl Res. 2018 Oct 15;10(10):3171-3185. eCollection 2018.
18. Wendy S. Garrett
Cancer and the microbiota
Science. 2015 Apr 3; 348(6230): 80–86.
19. Walser T, Cui X, Yanagawa J, et al
Smoking and lung cancer: the role of inflammation.
Proc Am Thorac Soc. 2008 Dec 1;5(8):811-5.
20. Chen L, Deng H, Cui H, et al
Inflammatory responses and inflammation-associated diseases in organs.
Oncotarget. 2017 Dec 14;9(6):7204-7218.
21. Oren M, Rotter V.
Mutant p53 gain-of-function in cancer.
Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a001107.
22. Ramer R, Walther U, Borchert P, et al
Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.
J Lipid Res. 2013 Nov;54(11):3116-29.
23. Alvira CM.
Nuclear factor-kappa-B signaling in lung development and disease: one pathway, numerous functions.
Birth Defects Res A Clin Mol Teratol. 2014 Mar;100(3):202-16.
24. Panday A, Inda ME, Bagam P, et al
Transcription Factor NF-ÈB: An Update on Intervention Strategies
Arch Immunol Ther Exp (Warsz). 2016 Dec;64(6):463-483.
25. Ting Liu, Lingyun Zhang, Donghyun Joo, et al
NF-ÈB signaling in inflammation
Signal Transduct Target Ther. 2017; 2: 17023.
26. Rahman MM, McFadden G.
Modulation of NF-ÈB signalling by microbial pathogens.
Nat Rev Microbiol. 2011 Apr;9(4):291-306.
27. Pasparakis M.
Role of NF-ÈB in epithelial biology.
Immunol Rev. 2012 Mar;246(1):346-58.
28. Cai Z, Tchou-Wong KM, Rom WN.
NF-kappaB in lung tumorigenesis.
Cancers (Basel). 2011 Dec 14;3(4):4258-68.
29. Rius J, Guma M, Schachtrup C, et al
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha.
Nature. 2008 Jun 5;453(7196):807-11.
30.Gupta D, Treon SP, Shima Y, Hideshima T, et al
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
Leukemia. 2001 Dec;15(12):1950-61
31.Yao L, Liu F, Hong L, Sun L, et al
The function and mechanism of COX-2 in angiogenesis of gastric cancer cells.
J Exp Clin Cancer Res. 2011 Jan 25;30:13.
32.Sobolewski C, Cerella C, Dicato M,,et al
The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies
Int J Cell Biol. 2010;2010:215158
33.Cao Y, Cao R, Hedlund EM.
Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
J Mol Med (Berl). 2008 Jul;86(7):785-9.
34. Balkwill FR, Capasso M, Hagemann T.
The tumor microenvironment at a glance
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6.
35. Samples J1, Willis M, Klauber-Demore N.
Targeting angiogenesis and the tumor microenvironment.
Surg Oncol Clin N Am. 2013 Oct;22(4):629-39.
36. Stacker SA, Achen MG.
The VEGF signaling pathway in cancer: the road ahead.
Chin J Cancer. 2013 Jun;32(6):297-302.
37. Murakami M, Simons M.
Fibroblast growth factor regulation of neovascularization.
Curr Opin Hematol. 2008 May;15(3):215-20.
38. Gately S, Li WW.
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy
Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11.
39. Ohe Y, Ohashi Y, Kubota K, et al
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Ann Oncol. 2007 Feb;18(2):317-23. Epub 2006 Nov 1.
40. Gutierrez M, Giaccone G.
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.
Eur Respir Rev. 2014 Mar 1;23(131):79-91.
41. Kazandjian D, Suzman DL, Blumenthal G, et al
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Oncologist. 2016 May;21(5):634-42.
42. Seidel JA, Otsuka A, Kabashima K.
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Front Oncol. 2018 Mar 28;8:86.
43. Hijová E, Šoltésová A, Salaj R, et al
Preventive use of Lactobacillus plantarum LS/07 and inulin to relieve symptoms of acute colitis.
Acta Biochim Pol. 2015;62(3):553-7.
44. Scagliotti G, Novello S, von Pawel J, et al
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
J Clin Oncol. 2010 Apr 10;28(11):1835-42.
45. Schiller JH, Harrington D, Belani CP, et al
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
N Engl J Med. 2002 Jan 10;346(2):92-8.
46. Jackson AL, Zhou B, Kim WY.
HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer.
Expert Opin Ther Targets. 2010 Oct;14(10):1047-57.
47. Hamik A, Wang B, Jain MK.
Transcriptional regulators of angiogenesis.
Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):1936-47. Epub 2006 Jun 15.
48. Peng L, Kang S, Yin Z, et al
Antibacterial activity and mechanism of berberine against Streptococcus agalactiae.
Int J Clin Exp Pathol. 2015 May 1;8(5):5217-23. eCollection 2015.
49. Wang Y, Zhang S.
Berberine suppresses growth and metastasis of endometrial cancer cells via miR-101/COX-2.
Biomed Pharmacother. 2018 Jul;103:1287-1293.
50. Eski M, Sahin I, Sengezer M,et al
Thalidomide decreases the plasma levels of IL-1 and TNF following burn injury: is it a new drug for modulation of systemic inflammatory response.
51. N. Feng, H. Chen, S. Fu,et al
HIF-1¿ and HIF-2¿ induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide
Scientific Reports volume 6, Article number: 27280 (2016)
52. Li X, Liu X, Wang J, et al
Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.
Anticancer Res. 2003 May-Jun;23(3B):2481-7.
53. Li X1, Liu X, Wang J, et al
Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells.
Int J Mol Med. 2003 Jun;11(6):785-90.
54. M. J. Rezaie, A. Rostamzadeh, G.Keshavarz et al
Effect of Thalidomide on Cox-2 expression in bleomycin-induced
pulmonary fibrosis in mice
Biomedical Research and Therapy, 6(1):2974-2982
55. Brodie SA, Brandes JC.
Could valproic acid be an effective anticancer agent? The evidence so far.
Expert Rev Anticancer Ther. 2014 Oct;14(10):1097-100.
56. Geller LT, Barzily-Rokni M, Danino T, et al
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Science. 2017 Sep 15;357(6356):1156-1160.
57. Markowiak P, Śliżewska K.
Effects of Probiotics, Prebiotics, and Synbiotics on Human Health.
Nutrients. 2017 Sep 15;9(9). pii: E1021.
58. Kaji I, Karaki S, Kuwahara A.
Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release.
59. Wang H, Zhu C, Ying Y, et al
Metformin and berberine, two versatile drugs in treatment of common metabolic diseases.
Oncotarget. 2017 Sep 11;9(11):10135-10146.
60. Zou K, Li Z1, Zhang Y, et al
Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system.
Acta Pharmacol Sin. 2017 Feb;38(2):157-167.
61. Sun H, Wang N, Cang Z, et al
Modulation of Microbiota-Gut-Brain Axis by Berberine Resulting in Improved Metabolic Status in High-Fat Diet-Fed Rats.
Obes Facts. 2016;9(6):365-378.
62. Liu T, Guo F, Zhu X,et al
Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.
Exp Ther Med. 2017 Dec;14(6):5251-5257.
63. Kim HJ, Yim GW, Nam EJ, et al
Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3.
Cancer Res Treat. 2014 Jan;46(1):81-92.
64. Tempfer CB, Schultheis B, Hilal Z,et al
Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature.
Oncol Lett. 2017 Sep;14(3):3327-3336.
65. Grösch S, Maier TJ, Schiffmann S, et al
Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors
J Natl Cancer Inst. 2006 Jun 7;98(11):736-47.
66. Venkataramani V, Rossner C, Iffland L,
Histone Deacetylase Inhibitor Valproic Acid Inhibits Cancer Cell Proliferation via Down-regulation of the Alzheimer Amyloid Precursor Protein
J Biol Chem. 2010 Apr 2;285(14):10678-89.
67. Jung GA, Yoon JY, Moon BS,et al
Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway
BMC Cell Biol. 2008 Dec 9;9:66.
68. Sun L, Coy DH.
Anti-Convulsant Drug Valproic Acid in Cancers and in Combination Anti-Cancer Therapeutics. Mod Chem appl 2:118.
69. Schiffmann I, Greve G, Jung M, et al
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.
Epigenetics. 2016 Dec;11(12):858-870. Epub 2016 Nov 15.
70. Villalona-Calero M, Schaaf L, Phillips G,et al
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Cancer Chemother Pharmacol. 2007 Jan;59(1):23-33. Epub 2006 May 10.
71. Murugavel S, Bugyei-Twum A, Matkar PN et al
Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching.
Front Pharmacol. 2018 Jul 11;9:737